Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies

Kenneth Paris, Elie Haddad, Michael Borte, Nicholas Brodszki, Beáta Dérfalvi, L. Máródi, Iftikhar Hussain, Amy Darter, Werner Engl, Heinz Leibl, Barbara McCoy, Leman Yel

Research output: Article

Abstract

Aim: To assess Ig20Gly tolerability in pediatric patients with primary immunodeficiencies. Patients & methods: Infusion parameters and tolerability were analyzed in pediatric patients (aged 2-5 years [n = 6], 6-11 years [n = 22] and 12-17 years [n = 22]) receiving Ig20Gly in two Phase II/III trials. Results: Of 2624 Ig20Gly infusions, >99% did not require any rate reduction, interruption or discontinuation due to adverse events (AEs). Median maximum infusion rates and volumes/site were higher in patients 12-17 years of age (30 ml/h/site; 30 ml/site) versus 6-11 years (20 ml/h/site; 15 ml/site) and 2-5 years (18 ml/h/site; 14 ml/site). Rates of causally related systemic and local AEs (0.009 and 0.063 AEs/infusion) were low. Conclusion: Ig20Gly infused at relatively high rates and volumes was well tolerated in children.

Original languageEnglish
Pages (from-to)397-406
Number of pages10
JournalImmunotherapy
Volume11
Issue number5
DOIs
Publication statusPublished - ápr. 1 2019

Fingerprint

Immunoglobulins
Pediatrics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. / Paris, Kenneth; Haddad, Elie; Borte, Michael; Brodszki, Nicholas; Dérfalvi, Beáta; Máródi, L.; Hussain, Iftikhar; Darter, Amy; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Yel, Leman.

In: Immunotherapy, Vol. 11, No. 5, 01.04.2019, p. 397-406.

Research output: Article

Paris, K, Haddad, E, Borte, M, Brodszki, N, Dérfalvi, B, Máródi, L, Hussain, I, Darter, A, Engl, W, Leibl, H, McCoy, B & Yel, L 2019, 'Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies', Immunotherapy, vol. 11, no. 5, pp. 397-406. https://doi.org/10.2217/imt-2018-0088
Paris, Kenneth ; Haddad, Elie ; Borte, Michael ; Brodszki, Nicholas ; Dérfalvi, Beáta ; Máródi, L. ; Hussain, Iftikhar ; Darter, Amy ; Engl, Werner ; Leibl, Heinz ; McCoy, Barbara ; Yel, Leman. / Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. In: Immunotherapy. 2019 ; Vol. 11, No. 5. pp. 397-406.
@article{fcd80cde8ee043d4bcd6cd1478351fe8,
title = "Tolerability of subcutaneous immunoglobulin 20{\%}, Ig20Gly, in pediatric patients with primary immunodeficiencies",
abstract = "Aim: To assess Ig20Gly tolerability in pediatric patients with primary immunodeficiencies. Patients & methods: Infusion parameters and tolerability were analyzed in pediatric patients (aged 2-5 years [n = 6], 6-11 years [n = 22] and 12-17 years [n = 22]) receiving Ig20Gly in two Phase II/III trials. Results: Of 2624 Ig20Gly infusions, >99{\%} did not require any rate reduction, interruption or discontinuation due to adverse events (AEs). Median maximum infusion rates and volumes/site were higher in patients 12-17 years of age (30 ml/h/site; 30 ml/site) versus 6-11 years (20 ml/h/site; 15 ml/site) and 2-5 years (18 ml/h/site; 14 ml/site). Rates of causally related systemic and local AEs (0.009 and 0.063 AEs/infusion) were low. Conclusion: Ig20Gly infused at relatively high rates and volumes was well tolerated in children.",
keywords = "Ig20Gly, immunodeficiencies, pediatric, tolerability",
author = "Kenneth Paris and Elie Haddad and Michael Borte and Nicholas Brodszki and Be{\'a}ta D{\'e}rfalvi and L. M{\'a}r{\'o}di and Iftikhar Hussain and Amy Darter and Werner Engl and Heinz Leibl and Barbara McCoy and Leman Yel",
year = "2019",
month = "4",
day = "1",
doi = "10.2217/imt-2018-0088",
language = "English",
volume = "11",
pages = "397--406",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies

AU - Paris, Kenneth

AU - Haddad, Elie

AU - Borte, Michael

AU - Brodszki, Nicholas

AU - Dérfalvi, Beáta

AU - Máródi, L.

AU - Hussain, Iftikhar

AU - Darter, Amy

AU - Engl, Werner

AU - Leibl, Heinz

AU - McCoy, Barbara

AU - Yel, Leman

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Aim: To assess Ig20Gly tolerability in pediatric patients with primary immunodeficiencies. Patients & methods: Infusion parameters and tolerability were analyzed in pediatric patients (aged 2-5 years [n = 6], 6-11 years [n = 22] and 12-17 years [n = 22]) receiving Ig20Gly in two Phase II/III trials. Results: Of 2624 Ig20Gly infusions, >99% did not require any rate reduction, interruption or discontinuation due to adverse events (AEs). Median maximum infusion rates and volumes/site were higher in patients 12-17 years of age (30 ml/h/site; 30 ml/site) versus 6-11 years (20 ml/h/site; 15 ml/site) and 2-5 years (18 ml/h/site; 14 ml/site). Rates of causally related systemic and local AEs (0.009 and 0.063 AEs/infusion) were low. Conclusion: Ig20Gly infused at relatively high rates and volumes was well tolerated in children.

AB - Aim: To assess Ig20Gly tolerability in pediatric patients with primary immunodeficiencies. Patients & methods: Infusion parameters and tolerability were analyzed in pediatric patients (aged 2-5 years [n = 6], 6-11 years [n = 22] and 12-17 years [n = 22]) receiving Ig20Gly in two Phase II/III trials. Results: Of 2624 Ig20Gly infusions, >99% did not require any rate reduction, interruption or discontinuation due to adverse events (AEs). Median maximum infusion rates and volumes/site were higher in patients 12-17 years of age (30 ml/h/site; 30 ml/site) versus 6-11 years (20 ml/h/site; 15 ml/site) and 2-5 years (18 ml/h/site; 14 ml/site). Rates of causally related systemic and local AEs (0.009 and 0.063 AEs/infusion) were low. Conclusion: Ig20Gly infused at relatively high rates and volumes was well tolerated in children.

KW - Ig20Gly

KW - immunodeficiencies

KW - pediatric

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=85061973800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061973800&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0088

DO - 10.2217/imt-2018-0088

M3 - Article

C2 - 30626238

AN - SCOPUS:85061973800

VL - 11

SP - 397

EP - 406

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -